Calithera Biosciences, Inc.
CALAInactive ticker- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001496671
No open-market purchases or sales by Calithera Biosciences, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
This ticker is no longer on the SEC's list of tickers: the company may have been delisted, or the ticker has changed.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 0
- Q2 2026
- 13F value
- $0
- Reported value at the end of Q2 2026
- Superinvestors holding
- 0
- At the end of Q2 2026
Superinvestors holding CALA, Q2 2026
No superinvestor reported holding CALA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Calithera Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 31, 2023 (view filing)7:04 PM ET | Jan 27 | 4 days | Pakianathan DeepikaDirector | SSale | −121.3K | $0.3858 | −$46.8K | −100.0%0 after | 2 lots |
| Nov 12, 2021 (view filing) | Nov 10-11 | 2 days | Orford KeithDirector | SSale | −78.2K | $0.8723 | −$68.2K | −54.2%66.1K after | 2 lots |
| Nov 10, 2021 (view filing) | Nov 10 | Same day | Molineaux SusanPRESIDENT & CEO | PPurchase | +100.0K | $0.85 | +$85.0K | +21.9%557.2K after | Duplicate filing |
| Nov 10, 2021 (view filing) | Nov 10 | Same day | Drachman Jonathan GDirector | PPurchase | +200.0K | $0.86 | +$172.0K | New position200.0K after | |
| Nov 10, 2021 (view filing) | Nov 10 | Same day | Molineaux ChristopherSR. VP, DEVELOPMENT | PPurchase | +100.0K | $0.85 | +$85.0K | +21.9%557.2K after | |
| Nov 9, 2021 (view filing) | Nov 9 | Same day | Orford KeithDirector | SSale | −51.8K | $0.84 | −$43.5K | −26.4%144.3K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Calithera Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding CALA in 13F filings for Q2 2026.